BALDEMAR COVARRUBIAS, MD

Sarscov2 vac 50 mcg/0.5ml im

Established patient office or other outpatient visit, 30-39 minutes

Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit

Established patient office or other outpatient visit, 20-29 minutes

Influenza vaccine, quadrivalent inactivated, 0.5 ml dosage

Established patient office or other outpatient visit, 10-19 minutes

Detection test by immunoassay technique for severe acute respiratory syndrome coronavirus

Physician or allowed practitioner certification for medicare-covered home health services under a home health plan of care (patient not present), including contacts with home health agency and review of reports of patient status required by physicians and

Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report

Office or other outpatient visit for the evaluation and management of established patient that may not require presence of healthcare professional

Physician or allowed practitioner re-certification for medicare-covered home health services under a home health plan of care (patient not present), including contacts with home health agency and review of reports of patient status required by physicians a

Admn sarscov2 vacc 1 dose

Injection of drug or substance under skin or into muscle

Administration of influenza virus vaccine

Detection test by immunoassay technique for streptococcus, group a (strep)

Detection test by immunoassay with direct visual observation for influenza virus

Urinalysis, manual test

Hemoglobin a1c level

Injection, triamcinolone acetonide, not otherwise specified, 10 mg